Skip to main content
Premium Trial:

Request an Annual Quote

Cell Biosciences Names Execs, Exiqon Appoints CSO and CCO, Katz Joins Hudson Control as CSO

NEW YORK (GenomeWeb News) - Cell Biosciences has named three new members to its senior executive staff. The company has appointed Jason Novi to be CFO, Robert Gavin as VP of engineering, and Willhelm Lachnit as VP of research and development.
Novi formerly was VP of finance at Nektar Therapeutics, and he was director of finance at Molecular Devices for seven years. Gavin previously was director of engineering at MDS Analytical Technologies (previously Molecular Devices). Lachnit also was at Molecular Devices, and he previously worked at Roche and at Syntex.

Exiqon has hired Cynthia French to be chief scientific officer and Erik Holmlin to be chief commercial officer, the company said this week.

French formerly was VP of clinical services laboratory at Affymetrix, and she was VP and CSO at Specialty Laboratories. She also has worked at Quest Diagnostics, Plutiva, Bio-Rad Laboratories, Diagnostic Products Corporation, and Du Pont.

Holmlin had worked at BD Diagnostics and he was one of the founders of GeneOhm, which was purchased by BD Diagnostics in 2006.

Both French and Holmlin will be based at the company’s Oncotech subsidiary in California.

Hudson Control Group has hired Alan Katz to be chief scientific officer. Katz led a computational chemistry and drug development for 20 years, and he also worked with Wyeth Research (formerly Ayerst Research).

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.